La cadena de opciones muestra datos clave de las opciones de acciones de Maxeon Solar Technologies a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Maxeon Solar Technologies..

Maxeon Solar Technologies (NASDAQ:MAXN) Bolsa, Cadena de Opciones

Maxeon Solar Technologies

Maxeon Solar Technologies Ltd is engaged in the manufacturing and marketing of premium solar technology. It owns and operates solar cell and panel manufacturing facilities located in Malaysia, Mexico, and the Philippines. The company's primary products are the Maxeon line of interdigitated back contact (IBC) solar cells and panels, and the Performance line (formerly, P-Series) of shingled solar cells and panels. the Maxeon line of solar panels are the highest-efficiency solar panels on the market with an aesthetically pleasing design, and the Performance line of solar panels offers a high-value and cost-effective solution. It is targeted at residential and small-scale commercial customers across the globe. The company derives its revenue from the United States, France, Italy, and others.

Maxeon Solar Technologies, Ltd. - Ordinary Shares

Maxeon Solar Technologies Ltd

Tenable Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENB#NASDAQ">TENB</a>) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.28 by 28.57 percent. This is a 44 percent increase over earnings of $0.25 per share from the same period last year. The company reported quarterly sales of $239.14 million which beat the analyst consensus estimate of $233.74 million by 2.31 percent. This is a 10.73 percent increase over sales of $215.96 million the same period last year.

Earnings

Earnings Beats

News

TENB

Tenable Holdings Q1 Adj. EPS $0.36 Beats $0.28 Estimate, Sales $239.14M Beat $233.74M Estimate

Ribbon Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBBN#NASDAQ">RBBN</a>) sees Q2 sales of $210.000 million-$220.000 million vs $209.94 million analyst estimate.

Guidance

RBBN

Ribbon Communications Sees Q2 Sales $210.000M-$220.000M vs $209.94M Est

Seagate Tech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) reported quarterly earnings of $1.90 per share which missed the analyst consensus estimate of $2.09 by 9.09 percent. This is a 475.76 percent increase over earnings of $0.33 per share from the same period last year. The company reported quarterly sales of $2.16 billion which missed the analyst consensus estimate of $2.31 billion by 6.36 percent. This is a 30.51 percent increase over sales of $1.66 billion the same period last year.

Earnings Misses

Seagate Tech Hldgs Q3 Adj. EPS $1.90 Misses $2.09 Estimate, Sales $2.16B Miss $2.31B Estimate

LendingClub (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LC#NYSE">LC</a>) reported quarterly earnings of $0.10 per share which missed the analyst consensus estimate of $0.11 by 9.09 percent. This is a 9.09 percent decrease over earnings of $0.11 per share from the same period last year. The company reported quarterly sales of $217.71 million which beat the analyst consensus estimate of $214.30 million by 1.59 percent. This is a 20.49 percent increase over sales of $180.69 million the same period last year.

LendingClub Q1 EPS $0.10 Misses $0.11 Estimate, Sales $217.71M Beat $214.30M Estimate

Clearwater Paper (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLW#NYSE">CLW</a>) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.04) by 850 percent. This is a 136.89 percent decrease over earnings of $1.03 per share from the same period last year. The company reported quarterly sales of $378.20 million which missed the analyst consensus estimate of $387.00 million by 2.27 percent. This is a 23.78 percent decrease over sales of $496.20 million the same period last year.

Clearwater Paper Q1 EPS $(0.38) Misses $(0.04) Estimate, Sales $378.20M Miss $387.00M Estimate

AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) raises FY2025 Adj EPS guidance from $(0.64)-$(0.57) to $(0.55)-$(0.50) vs $(0.66) analyst estimate. Affirms FY2025 sales outlook from $517.00 million-$527.00 million to $517.00 million-$527.00 million vs $522.79 million estimate.

ATRC

AtriCure Raises FY2025 Adj EPS Guidance from $(0.64)-$(0.57) to $(0.55)-$(0.50) vs $(0.66) Est; Affirms FY2025 Sales Guidance of $517.00M-$527.00M vs $522.79M Est

Rogers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROG#NYSE">ROG</a>) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $0.25 by 8 percent. This is a 53.45 percent decrease over earnings of $0.58 per share from the same period last year. The company reported quarterly sales of $190.50 million which beat the analyst consensus estimate of $186.33 million by 2.24 percent. This is a 10.73 percent decrease over sales of $213.40 million the same period last year.

Rogers Q1 Adj. EPS $0.27 Beats $0.25 Estimate, Sales $190.50M Beat $186.33M Estimate

UMB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UMBF#NASDAQ">UMBF</a>) reported quarterly earnings of $2.58 per share which beat the analyst consensus estimate of $2.19 by 17.81 percent. This is a 4.45 percent increase over earnings of $2.47 per share from the same period last year. The company reported quarterly sales of $563.84 million which beat the analyst consensus estimate of $559.01 million by 0.86 percent. This is a 41.43 percent increase over sales of $398.68 million the same period last year.

UMBF

UMB Financial Q1 Adj. EPS $2.58 Beats $2.19 Estimate, Sales $563.84M Beat $559.01M Estimate

SOND

Sonder Holdings Receives Deficiency Letter From Nasdaq Related To Delayed Filing Of Annual Report On Form 10-K

Huron Consulting Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURN#NASDAQ">HURN</a>) affirms FY2025 Adj EPS guidance from $6.80-$7.60 to $6.80-$7.60 vs $7.16 analyst estimate. Affirms FY2025 sales outlook from $1.58 billion-$1.66 billion to $1.58 billion-$1.66 billion vs $1.62 billion estimate.

HURN

Huron Consulting Gr Affirms FY2025 Adj EPS Guidance of $6.80-$7.60 vs $7.16 Est; Affirms FY2025 Sales Guidance of $1.58B-$1.66B vs $1.62B Est

Ribbon Comms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBBN#NASDAQ">RBBN</a>) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $0.01 by 400 percent. This is a 200 percent decrease over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $181.00 million which missed the analyst consensus estimate of $191.66 million by 5.56 percent. This is a 0.74 percent increase over sales of $179.66 million the same period last year.

Ribbon Comms Q1 Adj. EPS $(0.03) Misses $0.01 Estimate, Sales $181.00M Miss $191.66M Estimate

Mondelez International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>) reported quarterly earnings of $0.74 per share which beat the analyst consensus estimate of $0.66 by 12.12 percent. This is a 22.11 percent decrease over earnings of $0.95 per share from the same period last year. The company reported quarterly sales of $9.31 billion which missed the analyst consensus estimate of $9.32 billion by 0.12 percent. This is a 0.25 percent increase over sales of $9.29 billion the same period last year.

MDLZ

Mondelez International Q1 Adj. EPS $0.74 Beats $0.66 Estimate, Sales $9.31B Miss $9.32B Estimate

PPG Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>) affirms FY2025 Adj EPS guidance from $7.75-$8.05 to $7.75-$8.05 vs $7.81 analyst estimate..

PPG Indus Affirms FY2025 Adj EPS Guidance of $7.75-$8.05 vs $7.81 Est

<ul>
<li>The Phase 3 ABTECT trials (Studies 105 and 106) evaluating obefazimod in patients with moderately to severely active ulcerative colitis successfully enrolled 1,275 participants, exceeding the target enrollment of 1,224 by 4%. &nbsp;</li>
<li>Top-line results from the 8-week induction trials anticipated in Q3 2025, with 44-week maintenance data on track for Q2 2026 and, if successful, NDA submission planned for H2 2026. &nbsp;</li>
<li>Blinded baseline characteristics align with pre-specified target population and are consistent with Phase 2b UC trial participant characteristics &nbsp;</li>
<li>Cash runway through ABTECT induction trials readout and into Q4 2025 &nbsp;</li>
</ul>
PARIS, France – April 29, 2025 – 10:05 PM CET – Abivax SA (PARIS:<a class="ticker" href="https://www.benzinga.com/stock/FR#PARIS">FR</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVX#NASDAQ">ABVX</a>) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the completion of enrollment for the Phase 3 ABTECT trials in patients with moderately to severely active ulcerative colitis.

ABVX

PARIS:FR

Abivax Completes Enrollment For Phase 3 ABTECT Trials In Patients With Moderately To Severely Active Ulcerative Colitis

Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) reported quarterly earnings of $2.76 per share which beat the analyst consensus estimate of $2.68 by 2.99 percent. This is a 9.96 percent increase over earnings of $2.51 per share from the same period last year. The company reported quarterly sales of $9.59 billion which beat the analyst consensus estimate of $9.55 billion by 0.46 percent. This is a 9.33 percent increase over sales of $8.78 billion the same period last year.

Visa Q2 Adj. EPS $2.76 Beats $2.68 Estimate, Sales $9.59B Beat $9.55B Estimate

Edison Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EIX#NYSE">EIX</a>) reported quarterly earnings of $1.37 per share which beat the analyst consensus estimate of $1.19 by 15.13 percent. This is a 21.24 percent increase over earnings of $1.13 per share from the same period last year. The company reported quarterly sales of $3.81 billion which missed the analyst consensus estimate of $4.13 billion by 7.63 percent. This is a 6.55 percent decrease over sales of $4.08 billion the same period last year.

Edison Intl Q1 Adj. EPS $1.37 Beats $1.19 Estimate, Sales $3.81B Miss $4.13B Estimate

<ul>
<li>QIAcuity digital PCR kits, assays and protocols for lentivirus-based therapies support quality control in cell and gene therapy manufacturing</li>
<li>Expansion underscores the commitment of QIAGEN to help accelerate the development of safe and effective biotherapeutics</li>
<li>New solutions support high-precision analytics for process development, batch release and regulatory compliance and enable a standardized workflow</li>
</ul>
QIAGEN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>, Frankfurt Prime Standard: QIA))) today announced the expansion of its cell and gene therapy (CGT) portfolio with an enhanced digital PCR (dPCR) workflow that now includes solutions for lentivirus-based applications, commonly used in the production of advanced treatments such as chimeric antigen receptor T-cell (CAR-T), a personalized form of cancer immunotherapy.
This expanded offering supports standardized, high-precision quality control (QC) workflows and strengthens the position of QIAGEN as a trusted partner for quality control, supporting biotech and biopharma companies, Contract Development and Manufacturing Organizations (CDMO) and therapy developers in CGT manufacturing.
"Cell and gene therapy developers face increasing demands for precise, scalable solutions to help ensure therapy safety and efficacy," said Justus Krause-Harder, Vice President and Head of Molecular Tools &amp; Oncology at QIAGEN. "With our expanded dPCR portfolio, we are not only meeting the needs of lentivirus-based therapies but also reaffirming our long-term commitment as a partner for quality control in CGT development and manufacturing."
The additions to QIAGEN's offering of dPCR solutions for lentiviral vectors and their characterization include:
<ul>
<li>The QIAcuity RCL Quant Kit detects replication-competent lentivirus (RCL), a key safety concern in lentiviral vector production. The kit uses clear step-by-step protocols to find even small amounts of RCL, helping therapy developers meet regulations and keep treatments safe.</li>
<li>The new QIAcuity CGT dPCR assays, including eight different wet-lab verified lentiviral targets, are designed for viral vector genome titration (measuring the amount of therapeutic virus particles) and vector copy number (VCN) determination (counting how many copies of a gene are inserted into each cell). The assays offer superior accuracy, reproducibility and speed on the QIAcuity Digital PCR System and enable singleplex and multiplex applications for a streamlined, high-throughput workflow. Together with QIAcuity nanoplates and dedicated master mixes, these assays deliver absolute quantification of viral titer (the concentration of virus particles in a sample) and vector copy number determination, which are crucial for biopharmaceutical manufacturing and quality control processes.</li>
<li>The new CGT Lentivirus Lysis Kit and protocol, combined with QIAcuity CGT dPCR assays, enables vector genome titer quantification with fewer hands-on steps, enhanced accuracy and repeatability. It supports standardized titer quantification from lentivirus particles, promotes robust QC and improved operating procedures, and is ideal for drug development and manufacturing in CGT.</li>
</ul>
These new solutions join the growing portfolio of cell and gene therapy dPCR assays for the biopharma market, including residual DNA quantification kits for commonly used production cell lines such as Human Embryonic Kidney 293 (HEK293), E. coli, and Chinese Hamster Ovary (CHO) cells, mycoplasma quantification kit, adeno-associated virus (AAV) application, viral titer assays and solutions to determine viral vector integrity.

Biotech

General

QGEN

QIAGEN Expands Digital PCR Portfolio With New Lentivirus Solutions To Strengthen Cell And Gene Therapy Quality Control

AMERISAFE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMSF#NASDAQ">AMSF</a>) reported quarterly earnings of $0.60 per share which missed the analyst consensus estimate of $0.61 by 1.64 percent. This is a 13.04 percent decrease over earnings of $0.69 per share from the same period last year. The company reported quarterly sales of $72.60 million which missed the analyst consensus estimate of $76.78 million by 5.45 percent. This is a 9.81 percent decrease over sales of $80.49 million the same period last year.

AMSF

AMERISAFE Q1 Adj. EPS $0.60 Misses $0.61 Estimate, Sales $72.60M Miss $76.78M Estimate

Huron Consulting Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURN#NASDAQ">HURN</a>) reported quarterly earnings of $1.68 per share which beat the analyst consensus estimate of $1.16 by 44.83 percent. This is a 36.59 percent increase over earnings of $1.23 per share from the same period last year. The company reported quarterly sales of $395.69 million which beat the analyst consensus estimate of $389.27 million by 1.65 percent. This is a 11.16 percent increase over sales of $355.96 million the same period last year.

Huron Consulting Gr Q1 Adj. EPS $1.68 Beats $1.16 Estimate, Sales $395.69M Beat $389.27M Estimate

PPG Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>) reported quarterly earnings of $1.72 per share which beat the analyst consensus estimate of $1.62 by 6.17 percent. This is a 7.53 percent decrease over earnings of $1.86 per share from the same period last year. The company reported quarterly sales of $3.68 billion which beat the analyst consensus estimate of $3.67 billion by 0.45 percent. This is a 14.54 percent decrease over sales of $4.31 billion the same period last year.

PPG Indus Q1 Adj. EPS $1.72 Beats $1.62 Estimate, Sales $3.68B Beat $3.67B Estimate

Commodities

Stock Split

Press Releases

Maxeon Receives Nasdaq Notification and is Proceeding with Approved Reverse Stock Split

Pomerantz Law Firm Announces the Filing of a Class Action Against Maxeon Solar Technologies, Ltd. - MAXN

Maxeon Announces CEO Leadership Transition

Maxeon Provides Update on CBP Detention of its Solar Panels

Maxeon Announces Restructuring of Business Portfolio

Maxeon Solar Technologies Announces Third Quarter 2024 Financial Results

Maxeon and Tongwei Solar Announce Settlement Agreement Resolving Patent Infringement Lawsuit

Maxeon Provides Strategic Business Update

MAXN

Ascent Solar Technologies, Inc - Common Stock

Ascent Solar Technologies

Blaize Holdings

Datavault AI

GCT Semiconductor Holding, Inc. Common Stock

GCT Semiconductor Hldgs

GSI Technology

Intchains Group Limited - American Depositary Shares

Intchains Gr

Kopin

SemiLEDs

Mobix Labs

Everspin Technologies, Inc. - Common Stock

Everspin Technologies

Magnachip Semiconductor Corporation Common Stock

MagnaChip Semiconductor

Nano Labs

Peraso

Pixelworks

QuickLogic

Semilux International Ltd. - Ordinary Shares

Semilux International

SmartKem

Sequans Communications S.A. American Depositary Shares (each representing ten (10) Ordinary Shares)

Comments

Maxeon Solar Technologies

Maxeon Solar Technologies (MAXN) Opciones

Maxeon Solar Technologies (NASDAQ:MAXN) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL